Virax Biolabs Announces $5M Ordinary Shares Offering

Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, announced today that it has entered into definitive agreements for the purchase and sale of 12,500,000 ordinary shares (or ordinary share equivalents) and preferred investment options to purchase up to an aggregate of 12,500,000 ordinary shares at a purchase price of $0.40 per ordinary share and associated preferred investment option in a private placement .

The gross proceeds from the private placement are expected to be $5 million, before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from the private placement for working capital and other general corporate purposes. The private placement is expected to close on or about December 4, 2025, subject to the satisfaction of customary closing conditions.